β-Lactam/β-Lactamase Inhibitor Combinations Non-Susceptible ESBL-Producing <i>Enterobacteriaceae</i> Bloodstream Infections: An Underestimated Clinical Entity.

Infect Drug Resist · 2025 · PMC12126115 · PMID 40454310

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

The proportion of BnESBL-E-BSI within the ESBL-BSI cohort ranged from 35.23% to 47.29% between 2017 and 2019, demonstrating an increasing trend over the years ( Appendix 1 ).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

β-Lactam/β-Lactamase Inhibitor Combinations Non-Susceptible ESBL-Producing &lt;i&gt;Enterobacteriaceae&lt;/i&gt; Bloodstream Infections: An Underestimated Clinical Entity.

The sentences

β-Lactam/β-Lactamase Inhibitor Combinations Non-Susceptible ESBL-Producing <i>Enterobacteriaceae</i> Bloodstream Infections: An Underestimated Clinical Entity.